Ideas2IT Blog

Technology due diligence in private equity has improved significantly over the last decade. Most firms now review systems, vendors, security posture, and high-level architecture before closing a deal.

Private equity firms do not evaluate technology partners the way most vendors expect. While diligence conversations focus on tools, platforms, credentials, and prior experience, real evaluation begins after the deal closes, when execution pressure increases and portfolio realities surface.

Every acquisition hides technology risk, including legacy code, brittle integrations, undocumented workflows, fragile data pipelines, and engineering practices held together by tribal knowledge. None of this appears in IMs or management decks, and none of it is quantified in the valuation.

At The Product Folks Meetup at Ideas2IT HQ, over 50 product managers, developers, and community leaders came together to answer a critical question: How can product teams use no-code tools like n8n to operate with engineering-grade efficiency without diverting developer bandwidth?

The promise of artificial intelligence in healthcare has never been greater. From diagnostic support and treatment planning to payer claims automation and patient-intake optimisation, AI holds the potential to transform care delivery, reduce cost and unlock entirely new workflows.Yet, this promise comes with paradoxes. On one hand, clinician adoption is accelerating, reflecting demand for smarter tools. On the other, significant gaps remain in validation, governance and operational safety.

Selenium has been a bridge between how developers build and how users experience the web. Since its origin in 2004 as a lightweight JavaScript test runner, Selenium’s steady climb to becoming a W3C-standardized automation layer mirrors the broader evolution of web applications themselves: from static pages to dynamic, API-rich, real-time experiences.